Globus Medical, Inc. $GMED Stock Position Raised by SG Americas Securities LLC

SG Americas Securities LLC increased its stake in Globus Medical, Inc. (NYSE:GMED) by 523.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 327,689 shares of the medical device company’s stock after purchasing an additional 275,150 shares during the quarter. SG Americas Securities LLC’s holdings in Globus Medical were worth $18,767,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. EverSource Wealth Advisors LLC lifted its stake in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the period. Advisors Asset Management Inc. bought a new position in Globus Medical in the second quarter valued at about $28,000. CENTRAL TRUST Co bought a new position in shares of Globus Medical in the 2nd quarter valued at about $39,000. Headlands Technologies LLC boosted its stake in Globus Medical by 485.4% in the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after acquiring an additional 631 shares during the last quarter. Finally, Signaturefd LLC boosted its position in shares of Globus Medical by 41.1% in the 2nd quarter. Signaturefd LLC now owns 958 shares of the medical device company’s stock worth $57,000 after purchasing an additional 279 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

Insider Activity at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $86.00, for a total transaction of $2,150,000.00. Following the completion of the sale, the director owned 516,275 shares of the company’s stock, valued at approximately $44,399,650. The trade was a 4.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Kelly Huller sold 7,500 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $90.00, for a total transaction of $675,000.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 86,042 shares of company stock worth $7,419,030 in the last quarter. 18.51% of the stock is owned by corporate insiders.

Globus Medical Stock Up 4.4%

GMED opened at $94.48 on Friday. Globus Medical, Inc. has a 12-month low of $51.79 and a 12-month high of $101.40. The business has a 50 day moving average of $85.12 and a 200-day moving average of $67.63. The stock has a market cap of $12.65 billion, a price-to-earnings ratio of 30.48, a PEG ratio of 1.61 and a beta of 1.06.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, November 6th. The medical device company reported $1.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.39. Globus Medical had a return on equity of 11.52% and a net margin of 15.30%.The business had revenue of $769.05 million for the quarter, compared to analysts’ expectations of $734.58 million. During the same quarter in the prior year, the business earned $0.83 EPS. The firm’s revenue for the quarter was up 22.9% on a year-over-year basis. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. As a group, analysts expect that Globus Medical, Inc. will post 3.44 earnings per share for the current year.

Analyst Ratings Changes

GMED has been the topic of several research analyst reports. Wells Fargo & Company raised their price objective on Globus Medical from $66.00 to $79.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Morgan Stanley boosted their target price on Globus Medical from $70.00 to $100.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Bank of America upgraded shares of Globus Medical from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $65.00 to $91.00 in a report on Friday, November 7th. Barclays increased their target price on shares of Globus Medical from $106.00 to $114.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. Finally, Citigroup reissued a “market perform” rating on shares of Globus Medical in a research report on Thursday. Eight analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Globus Medical currently has an average rating of “Moderate Buy” and a consensus target price of $97.00.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.